Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
Eligibility Criteria
- * Aim 1 Tissue
- * Cases:
- * Patient has a biopsy confirmed diagnosis of target histology
- * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
- * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without
- * Controls:
- * Patient does not have the diagnosis of target histology
- * Aim 2 Blood
- * Cases:
- * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
- * Controls:
- * Patient does not have a diagnosis of the target histology
- * Aim 3 Urine
- * Cases:
- * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
- * Controls:
- * Patient does not have a diagnosis of the target histology
- * Aim 1 Tissue
- * Cases and Controls:
- * Patient has had any transplants prior to tissue collection
- * Patient has received chemotherapy class drugs within 5 years prior to tissue collection
- * Cases:
- * Patient has had radiation to the current target lesion prior to tissue collection
- * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
- * Patient has bilateral breast cancer/Ductal carcinoma in situ (DCIS)
- * Aim 2 Blood
- * Cases and Controls:
- * Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)
- * Patient has received chemotherapy class drugs in the 5 years prior to blood collection
- * Patient has had any prior radiation therapy to the target lesion prior to blood collection
- * Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection
- * Cases:
- * Patient has had an intervention to completely remove current target pathology
- * The current target pathology is a recurrence
- * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
- * Patient has bilateral breast cancer/DCIS
- * Aim 3 Urine
- * Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)
- * Patient has received chemotherapy class drugs in the 5 years prior to urine collection
- * Patient has had any prior radiation therapy to the target lesion prior to urine collection
- * Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection
- * The current target pathology is a recurrence
- * Patient has chronic indwelling urinary catheter
- * Patient has had a urinary tract infection within the 14 days prior to sample collection
- * If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer
- * Cases:
- * Patient has had an intervention to completely remove current target pathology
- * The current target pathology is a recurrence
- * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles \[estrogen receptor (ER)/human epidermal growth factor receptor 2 (HER2)/progesterone receptor (PR)\] status differ; if multiple masses are present and not all are tested then exclude patient)
- * Patient has bilateral breast cancer/DCIS
Ages Eligible for Study
18 Years to
Sexes Eligible for Study
ALL
Accepts Healthy Volunteers
Yes